Panacea Biotec Limited has announced receiving a Letter of Award from the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India, for the supply of Diphtheria and Tetanus Vaccine worth ₹20.79 crore. The Letter of Award was dated April 10, 2026, and the company disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Contract Details and Specifications

The contract involves the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP, commonly referred to as Td Vaccine. The supply will be executed in several tranches over an extended period, demonstrating the scale and importance of this government contract.

Execution Timeline and Supply Schedule

The vaccine supply is scheduled to commence from September 2026 and will continue until December 2028, spanning over two years. This extended timeline indicates a substantial and sustained supply commitment that will contribute to the company's revenue stream over the contract period. The phased delivery approach in several tranches allows for systematic distribution and quality management throughout the contract duration.

Regulatory Compliance and Disclosure

Panacea Biotec has fulfilled all regulatory disclosure requirements under SEBI LODR Regulations. The company confirmed that this is a domestic contract with no related party transactions involved. Additionally, the promoter/promoter group/group companies have no interest in the entity that awarded the contract, ensuring transparency in the business relationship.

Strategic Significance

This government contract represents a significant business development for Panacea Biotec's vaccine division. The award from CMSS, a key government procurement agency for medical supplies, validates the company's manufacturing capabilities and regulatory compliance standards. The contract strengthens Panacea Biotec's position in the domestic vaccine market and demonstrates the government's confidence in the company's ability to deliver quality pharmaceutical products for public health programs.

Panacea Biotec Limited has informed stock exchanges about receiving four awards from the Industrial Tribunal, S.A.S. Nagar, Mohali, pursuant to Regulation 30 of SEBI LODR Regulations. The company disclosed this development on April 10, 2026, following receipt of the tribunal communications on April 9, 2026.

Tribunal Awards Details

The Industrial Tribunal, presided over by an Additional District Judge, issued four awards dated March 19, 2026, with significant implications for the company's workforce management. The tribunal's decisions encompass multiple aspects of worker rights and compensation.

Company's Response and Legal Position

Panacea Biotec has outlined its stance regarding the tribunal awards, emphasizing its legal options and expected financial implications. The company maintains that the awards present grounds for legal challenge.

Key aspects of the company's response include:

• The awards are considered challengeable based on legal opinion
• No material adverse impact expected on financial, operational, or other activities
• Process initiated to file appeals before the Punjab and Haryana High Court
• Appropriate legal action being pursued against the orders

Regulatory Compliance

The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company provided comprehensive details as required under Regulation 30, including the nature of communication, receiving authority, and expected implications.

The company has indicated that no penalties, restrictions, or sanctions were imposed pursuant to the communication, and no aberrations or non-compliances were identified by the authority. Panacea Biotec continues to assess the situation while preparing its legal response to challenge the tribunal's decisions through appropriate judicial channels.